Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29323536 | 1.00 | ALDH1A1 (0.44) | ALDH1A1CCR5HTR2CHTR6EPHX1 | |
| SCHEMBL399242 | 1.00 | ALDH1A1 (0.44) | ALDH1A1CCR5HTR2CHTR6EPHX1 | |
| SCHEMBL29323535 | 1.00 | ALDH1A1 (0.44) | ALDH1A1CCR5HTR2CHTR6EPHX1 | |
| SCHEMBL24364098 | 1.00 | ALDH1A1 (0.44) | ALDH1A1CCR5HTR2CHTR6EPHX1 | |
| SCHEMBL2379871 | 1.00 | ALDH1A1 (0.44) | ALDH1A1CCR5HTR2CHTR6EPHX1 | |
| SCHEMBL24364095 | 1.00 | ALDH1A1 (0.44) | ALDH1A1CCR5HTR2CHTR6EPHX1 | |
| SCHEMBL29323538 | 1.00 | ALDH1A1 (0.44) | ALDH1A1CCR5HTR2CHTR6EPHX1 | |
| SCHEMBL24364102 | 1.00 | ALDH1A1 (0.44) | ALDH1A1CCR5HTR2CHTR6EPHX1 | |
| SCHEMBL22545893 | 1.00 | ALDH1A1 (0.44) | ALDH1A1CCR5HTR2CHTR6EPHX1 | |
| SCHEMBL27763804 | 1.00 | ALDH1A1 (0.44) | ALDH1A1CCR5HTR2CHTR6EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | ALDH1A1 128/4885CCR5 486/4885HTR2C 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.